Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Crew Davis felt at home during a weekend visit and signaled his intent to both coaches before he left Chapel Hill on Sunday.

Wall Street drifted through a mixed day of trading as rising fashion and cigarette stocks worked against drops for Ford Motor ...

Wall Street finished mixed Thursday as strong fashion and tobacco stocks offset Ford’s drop. The post appeared first on TV ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Wall Street is drifting as drops for Ford Motor and Qualcomm work against buoyant fashion and cigarette stocks. The S&P 500 ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Eli Lilly (LLY) reported in-line fourth-quarter sales on Thursday, while reiterating a 2025 revenue guidance that implies the top line will grow at the same pace as it did last year. Revenue climbed ...